Pulmonary hypertension (PH) in neonates, infants, children, adolescents, and young adults is a complex condition that can be associated with several cardiac, pulmonary, and systemic diseases contributing to morbidity and mortality. The underlying pulmonary hypertensive vascular disease (PHVD) is characterized by inflammation, pulmonary vascular remodeling, and angio-obliteration leading to elevated pulmonary arterial pressure and resistance, right ventricular dysfunction, left ventricular compression, and subsequent heart failure. Recent advancements in PH-targeted therapies and interventional-surgical procedures have contributed to the improvement in quality of life and survival in PH/PHVD. This paper gives an update on recent developments in the diagnosis and treatment of children and young adults with PH.
EPIDEMIOLOGY AND CLINICAL AND GENETIC RISK FACTORS
Although PAH is a rare disease, with an estimated prevalence of 15 to 50 cases/million adults (14, 15 ) and 2 to 16 cases/million children (16) (17) (18) , its frequency in certain at-risk groups is substantially higher (e.g., human immunodeficiency virus, systemic sclerosis, schistosomiasis). Of note, high-risk conditions and untreated congenital or acquired heart disease are far more common in developing countries with limited health care; hence, the true, global burden of PHVD is widely underestimated. Untreated idiopathic pulmonary arterial hypertension (IPAH) results in death within 2 to 3 years in adults and within 1 year after diagnosis in children (19) . In the pre-prostacyclin era (before 1995), children treated for IPAH had a poorer prognosis than adults, with a median survival of only 10 months versus 2.8 years, according to the National
Institutes of Health registry. In a U.K. cohort study ( reported clinical follow-up ended in 2007), the 5-year survival for children with PAH versus historical control subjects was still only 75%, with a freedom from death or transplantation of only 57% (17) . Pediatric PAH is associated with impaired growth, especially in younger children (0 to 5 years of age) and in those with PAH-CHD (20) . Such failure to thrive has been reported to be associated with a higher risk of death (17) .
Although adults with Eisenmenger syndrome (ES)-
PAH have a somewhat better survival than those with IPAH or heritable pulmonary arterial hypertension (HPAH), children with either PAH-CHD/PHVD-CHD or IPAH/HPAH have a similar 5-year mortality (29% vs.
25%, REVEAL [Registry to Evaluate Early and Long-
Term PAH Disease Management]) (1) . The severity of adult PAH-CHD tends to be underestimated because the apparent survival is related to the immortal bias selection of patients in reported registries. The PAH outcome with lung or heart-lung transplantation is far from ideal, with a median 5-year post-transplant survival of z45% to 55% for adults with PAH, although high-volume transplant centers may achieve better outcomes (21, 22) . Determinants of risk for poor outcome in children with PAH (hospitalization because of PAH deterioration, lung transplantation, and/or death) are summarized in Figure 1 , and a general diagnostic algorithm is outlined in Figure 2 .
Currently, the evidence for causation in human IPAH and HPAH is considered sufficient for abnormalities in the genes ACVRL1 (ALK-1), BMPR2, CAV1, ENG, and KCNK3; a causal role for mutations in the BMPR1B, NOTCH3, and SMAD9 genes is still unconfirmed (8). BMPR2 is the major gene associated with HPAH and IPAH. More than 300 BMPR2 mutations have been identified in PAH, and they are found in z75% HPAH and up to 25% of IPAH cases.
ETIOLOGIES AND PATHOBIOLOGY OF DISTINCT PH SUBGROUPS
PAH ASSOCIATED WITH CHD. Besides IPAH/HPAH (see the preceding text), a very common form of PAH diagnosed in childhood is PAH associated with CHD (all belong to group 1 PH) ( Table 2) . PAH-CHD often contains a pre-and/or post-tricuspid shunt lesion with or without pulmonary vascular disease (PVD) (23) , and distinct patterns of right ventricular (RV)
hypertrophy (24) . Children without PVD benefit from closure of a left-to-right (systemic-to-pulmonary) shunt early in life. However, children and young adults with CHD-PAH and significant PVD (PHVD; i.e., with reversal to a right-to-left shunt through the preformed shunt lesion (i.e., the so called ES) (25) . In 153 ES patients of the German National Register for
Congenital Heart Defects, the survival rate at 1, 5, and 10 years of follow-up was only 92%, 75%, and 57%, AVT in patients with CHD and shunt to assess operability ( Figure 3 ) With significant L-R shunt, the aforementioned criteria need some modification due to different underlying pathophysiology. The hemodynamic change that defines a positive response to AVT in PAH associated with a shunt defect (Qp:Qs >1.5; APAH-CHD shunt) for children should be considered as a more than 20% fall in PVRi and PVRi/SVRi with respective final values of PVRi <6 WU and PVRi/SVRi <0.3.
PAH associated with portal hypertension (PH group 1) is a rare condition in childhood that may occur in patients with liver disease and/or catheter-associated occlusion of the portal vein. PAH associated with connective tissue disease (CTD) (group 1 PH) is rare in childhood, with systemic sclerosis (up to 16%) and systemic lupus erythematosus probably carrying the highest risk for PAH development.
*Please note that PAWP #15 mm Hg is used in the European Society of Cardiology/European Respiratory Society 2016 Guidelines on Pulmonary Hypertension (2) and the 2013 PH World Symposium documents (11) , but that PAWP <15 mm Hg is used in the American Heart Association/American Thoracic Society Guidelines on pediatric PH (4). †Detailed hemodynamic definitions of PH (e.g., pre-capillary vs. post-capillary PH, value of the diastolic transpulmonary pressure gradient, definition of acute vasoreactivity in PAH-CHD shunt lesions and PAH without a shunt) are presented in Apitz et al. (53) .
APAH ¼ associated pulmonary arterial hypertension; AVT ¼ acute vasoreactivity testing; CHD ¼ congenital heart disease; HPAH ¼ heritable pulmonary arterial hypertension; IPAH ¼ idiopathic pulmonary arterial hypertension; L-R ¼ left-to-right; mLAP ¼ mean left atrial pressure; mPAP ¼ mean pulmonary artery pressure; PAH ¼ pulmonary arterial hypertension; PAWP ¼ pulmonary artery wedge pressure (synonymous with pulmonary capillary wedge pressure; not synonymous with pulmonary capillary pressure); PH ¼ pulmonary hypertension; PHVD ¼ pulmonary hypertensive vascular disease; PVRi ¼ pulmonary vascular resistance index; Qp ¼ pulmonary blood flow; Qs ¼ systemic blood flow; SVRi ¼ systemic vascular resistance index; TPG ¼ transpulmonary pressure gradient; WU ¼ Wood unit(s). VTI ratio [47] ; RV size [46] , LV size, and RV/LV ratio [48] ; RV stroke work [49] ; LV strain/strain rate [50] ;
and pulmonary artery acceleration time [51] Cardiac magnetic resonance (CMR) and CT are recommended noninvasive imaging modalities in the management of PH (52) . CMR offers the ability to assess ventricular function, blood flow, pulmonary perfusion, and myocardial tissue characteristics.
The main role of CT is to detect lung parenchymal disorders, thromboembolic disease, and vascular abnormalities such as pulmonary vein stenosis.
If sedation/anesthesia is needed for either CMR or CT, the risk needs to be balanced against the potential gain of information and its effect on the future therapy.
Diagnostic cardiac catheterization with acute pulmonary vasoreactivity testing (AVT) ( Table 1 ) should be performed in almost all patients before the initiation of PAH-targeted therapy (Figures 2 and 3 ).
Exceptions to this recommendation may be premature infants at high risk and/or very low body weight, and children with systemic vasculopathies or hemodynamic instability (53, 54) . A systematic catheterization protocol is required, and has been established in a very standardized manner for adults, and recently also for pediatric PH (53) . However, the complexity of childhood PVD often requires an individualized approach. However, therapeutic strategies for adult PAH have not been sufficiently studied in children, so that only Bronchopulmonary dysplasia Pre-and post-natal effect of exogenous risk factors on a structural and functional immature lung lead to post-natal impairment of angiogenesis and alveolarization associated with abnormal vascular function (increased tone, altered reactivity, impaired metabolism) and structure (smooth muscle cell proliferation, altered extra cellular matrix structure).
Congenital diaphragmatic hernia Developmental defect leading to severe vascular remodeling and rarefication of the vascular bed.
Lung hypoplasia (primary and secondary)
Genetic abnormalities or severe reduction in amniotic fluid leading to reduced pre-natal alveolar and vascular development.
Pulmonary interstitial glycogenosis
Rare, nonlethal pediatric form of interstitial lung disease, possible male predominance. Infants present with respiratory distress. Histological characteristics are the accumulation of monoparticulate glycogen in interstitial cells and associated lung growth abnormalities affecting all lung structures.
Pulmonary alveolar proteinosis Rare lung disease in which abnormal accumulation of surfactant occurs within the alveoli, interfering with gas exchange and affecting lung growth. Possible cause anti-GM-CSF autoantibodies.
Pulmonary lymphangiectasia Rare developmental pulmonary disorder characterized by pulmonary subpleural, interlobar, perivascular, and peribronchial lymphatic dilation.
SP abnormalities (SP-B and SP-C deficiency, ATP binding cassette A3 mutation, thyroid transcription factor 1/Nkx2.1 homeobox mutation)
a minority of these drugs has been officially approved for use in children.
Thus, appropriate therapies must be selected after a careful and comprehensive review in a PH expert referral center according to current international recommendations (3, 4, 58) . For example, PAH-CHD indeed requires a different treatment approach than PH associated with BPD or diaphragmatic hernia. The overall goal of PAH therapy is to induce: 1) pulmonary arterial vasodilation (plus, at best, antiinflammation and reverse remodeling); 2) to unload pressure and support the RV; 3) to avoid coronary ischemia and heart failure; and 4) to achieve improvement of clinical symptoms (i.e., exercise tolerance) (58). Of note, this approach does not necessarily apply to patients with PVOD or pulmonary 
capillary hemangiomatosis who can deteriorate with vasodilator therapy (however, some patients benefit from low-dose prostacyclin analog therapy).
If the responder criteria of acute vasoreactivity testing with inhaled NO þ oxygen in the cardiac catheterization laboratory are fulfilled (Table 1) Inhaled prostacyclin (iloprost, treprostinil) is used in children with progressive or persistent PAH, usually as Reprinted with permission from Schwachtgen et al. (98) .
NT-proBNP ¼ N-terminal pro-B-type natriuretic peptide; UCB ¼ umbilical cord blood. providers may consider upfront, early, or rapid sequence-targeted PAH therapy in the "intermediate-risk" group (between "lower-risk" and "higher-risk" in Figure 1 ). Use of all agents, aside from sildenafil and bosentan, is considered off-label in children (>1 year of age) in Europe.
Sildenafil dosing recommendations should follow EMA-approved dosing for children. Bosentan received the following dual grading: COR I, LOE B for children with PAH and Eisenmenger syndrome (ES), and COR IIa, LOE C for children with PAH without ES. Vasoreactivity testing is mainly useful for IPAH/HPAH, and these diagnoses form the basis for the body of published data. However, especially in pediatric PH, but also in adult PH, there may be PAH with a small, nonsignificant, or borderline pre-tricuspid (ASD, with Qp/Qs <1.5) or irrelevant post-tricuspid (VSD) LR shunt that does not explain the severe increase in PAP and PVR. In these occasions, patients with a progressive course may be better classified as having IPAH than PAH-CHD. In addition, positive vasoreactivity testing in the cardiac catheterization laboratory is associated with a better prognosis, and may help with deciding whether to close a left-to-right (¼ systemic-to-pulmonary arterial) shunt with borderline pulmonary vascular resistance. The addition of the reverse Potts shunt is a modification of the original figure, as there is according pediatric data available (92) . 
induces pulmonary vasodilation, and probably antiinflammatory and antiremodeling effects, with only a moderate effect on systemic blood pressure. Headaches, jaw pain, and airway reactivity (78) hansmann@gmail.com. Tables 1, 2 , and 5.
